Memantina Pensa

Memantine Hydrochloride, the active ingredient in Memantina Pensa, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat cognitive symptoms of Alzheimer’s disease in adults.

GNH USA supplies Memantina Pensa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride acts on the glutamatergic pathway and is indicated for dementia‑related conditions.

Alzheimer's disease (moderate to severe): improves cognition and daily functioning in patients with established disease. Alzheimer's disease (mild to moderate, as adjunct): may provide modest benefit when combined with a cholinesterase inhibitor. Behavioral symptoms of dementia: can reduce agitation and aggression in some patients.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Fatigue: feeling unusually tired or low‑energy.

Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions. - Hepatic injury: elevated liver enzymes or jaundice. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic impairment: monitor liver function tests periodically. History of seizures: use with caution and observe for new seizure activity. Concomitant NMDA antagonists: avoid co‑administration to prevent additive neuro‑toxicity. Pregnancy and breastfeeding: safety not established; weigh potential benefits against risks. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects. - Ketamine: combined NMDA blockade can potentiate central nervous system depression. - Other NMDA antagonists (e.g., dextromethorphan): risk of excessive inhibition of glutamatergic signaling.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors: may blunt cognitive benefit; monitor response. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Antihypertensives: possible additive hypotensive effect. - Diuretics: monitor electrolytes and renal function. - Anticholinergic agents: may exacerbate confusion or dizziness.